Brief: Veracyte Q1 Revenue USD 139.1 Million Vs. IBES Estimate USD 130 Million
05/05/2026 21:05
May 05 (Reuters) - Veracyte Q1 gross margin 73%. Q1 adjusted operating expenses USD 64.6 million Q1 net income USD 28.7 million
Recent news on Veracyte
See all newsU.S. STOCKS ON THE MOVE-Vor Biopharma, Fair Isaac Corp, Plug Power
U.S. STOCKS ON THE MOVE-Snowflake, Cboe, Oracle
US STOCKS ON THE MOVE-Veracyte, Staar Surgical, Corning
Veracyte gains on data supporting use of prostate cancer test to guide treatment decisions
Corrected: U.S. RESEARCH ROUNDUP-Abbvie, Amazon, Illumina